

# **Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies**

**April 21-23, 2017**

## **Friday, April 21, 2017**

### **Advanced Practice Providers: Side Effect Management and Dose Modification Strategies for Targeted Therapies**

**Moderator: Heather Paradis, MSN, ANP**

- |        |  |
|--------|--|
| 2:30pm | Registration   |
| 3:00pm | Welcome and Introductions  |
| 3:05pm | Integrating Cytogenetics and Molecular Data for AML Risk Stratification<br>Donna Adams, MSN, ANP |
| 3:35pm | Managing Patients Post CAR-T Infusion<br>Anne Beaven, MD   |
| 4:05pm | Cardio-oncology Toxicities and Management<br>Michael Khouri, MD                                  |
| 4:45pm | VTE Risk and Management in Hematologic Malignancies<br>Meredith Moorman, PharmD                  |

### **New Avenues in Stem Cell Therapy and Hematopathology**

**Moderator: David Rizzieri, MD**

- |        |  |
|--------|--|
| 3:00pm | The New WHO...What's Changing in the Classification Schema<br>Anand Lagoo, MD, PhD                         |
| 3:30pm | Application of 'Next Gen Sequencing' Chips for Those with Hematologic Malignancies<br>Chad McCall, MD, PhD |
| 4:00pm | BMT Update: 'In Home' Transplant - Bringing the Fight to your Door<br>Anthony Sung, MD                     |
| 4:45pm | Breakthrough Report: High Dose Therapy for Autoimmune Diseases Improves Survival!<br>Keith Sullivan, MD    |

**5:30 – 7:00pm RECEPTION**

## **Saturday, April 22, 2017**

### **7:00 – 7:45am Registration and Breakfast**

#### **Immunotherapy Highlights      Moderator: Joseph O. Moore, MD**

- 7:50am      Welcome and Pre-Session Survey
- 8:00am      Micro transplantation for Elderly Patients with AML  
Anthony Sung, MD
- 8:30am      Application of PD1 Inhibitors in Hematologic Malignancies  
Anas Younes, MD (MSKCC)
- 9:10am      Debate: The Best Immunotherapy for ALL: BITE vs CarT  
Anjali Advani, MD (Cleveland Clinic) vs. David Porter, MD (U. Penn)
- 9:55am      Break

#### **Leukemia Highlights      Moderator: David Rizzieri, MD**

- 10:10am      Pre-Session Survey
- 10:15am      Debate: We Can Cure CLL with Current / Soon to be Approved Agents...No Need for That ‘Nasty Transplant’  
Anthony Mato, MD (U. Penn) vs. Danielle Brander, MD
- 10:55am      Debate: All Patients with FLT3 + AML Should Receive Midostaurin Based Induction Therapy  
Pro: Richard Stone, MD (DFCI) vs. Con: Harry Erba, MD (University of Alabama)
- 11:35am      Leukemia Tumor Board with ARS  
Drs. Rizzieri, Advani, Erba, Porter and Stone

### **12:05 – 1:05pm      Lunch and Time with Exhibitors**

#### **Lymphoma and Benign Hematologic Highlights      Moderator: Thomas Ortel, MD**

- 1:05pm      Pre-Session Survey
- 1:15pm      Debate: Genomics for all DLBCL is Not as Useful as we Thought...OR IS IT?  
Anne Beaven, MD vs. Matthew McKinney, MD
- 1:55pm      Debate: Combined Modality Chemo-RT Should be the Standard Treatment for Stage I - IIFL  
Pro: Chris Kelsey, MD vs. Con: Anas Younes, MD (MSKCC)
- 2:40pm      IV vs. Oral Iron  
JJ Strouse, MD vs. Marilyn Telen, MD
- 3:20pm      Interactive Case Vignette  
  
DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)  
Thomas Ortel, MD
- 4:00pm      Adjourn For the Day

**Sunday, April 22, 2017**

**7:00am – 7:45am      Registration and Breakfast**

## **Highlights of CML and PMF Management and Lymphoma Tumor Board**

**Moderator: Louis Diehl, MD**

- |         |   |
|---------|---|
| 7:50am  | Pre-Session Survey  |
| 8:00am  | Stopping TKI's in CML – Are we There Yet?<br>Joseph O. Moore, MD  |
| 8:30am  | Debate: Mutation Status in PMF Should Guide Therapy<br>Lindsay Rein, MD vs. Brady Stein, MD (Northwestern)                          |
| 9:15am  | Lymphoma Tumor Board with Audience Response<br>Moderator: Louis Diehl, MD<br>Expert Panel Members: Drs. Beaven, McKinney and Younes |
| 10:45am | Post Session Survey and Q&A   |
| 11:00am | Adjourn   |